Tier 4 — mechanistic

Betaine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms of Action and Therapeutic Potential

Tatjana Radosavljevic, Jasmina Djuretic, Milica Brankovic, Janko Samardzic, Ivana Curuvija, Danijela Vucevic
Antioxidants (Basel, Switzerland) 2026 15(9):1209

Bibliography

PubMed
PMID 42792248
PubMed Central
PMC13603268
DOI
10.3390/antiox15091209
Funding
Reported funding/support: Faculty of Medicine, University of Belgradehttps://ror.org/02qsmb048 451-03-34/2026-03/200110 University of Belgrade—Faculty of Pharmacyhttps://ror.org/02qsmb048 451-03-33/2026-03/200161451-03-34/2026-03/200161This research was funded by the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia through two grant agreements with the Faculty of Medicine, University of Belgrade (No. 451-03-34/2026-03/200110) and University of Belgrade—Faculty of Pharmacy (Nos. 451-03-33/2026-03/200161 and 451-03-34/2026-03/200161).
Competing interests
Reported disclosure: The authors declare no conflicts of interest.

Study snapshot

DesignNarrative review
ModelEvidence synthesis; mixed research models
SamplePublished literature; no newly enrolled participant cohort
InterventionReview of betaine-related evidence; no single assigned intervention
DurationEvidence review; source-specific study durations vary
EndpointsBetaine biology; Clinical and mechanistic evidence

What the study showed, in plain terms

Published in 2026, this source examined mechanistic and clinical reviews. Its evidence base was Published literature; no newly enrolled participant cohort. It evaluated Review of betaine-related evidence; no single assigned intervention across Evidence review; source-specific study durations vary.

Reviews recent MASLD mechanisms and concludes that clinical therapeutic efficacy remains unestablished.

Consistent animal mechanisms have not yet resolved the limited human trial evidence or an effective treatment strategy.

Continue with TMG Data Center

Continue with TMG and Liver Health: Human Trials Behind the Claims

Key findings

  • Reviews recent MASLD mechanisms and concludes that clinical therapeutic efficacy remains unestablished.
  • The recorded outcome domains were Betaine biology; Clinical and mechanistic evidence.

What this study can and cannot tell us

  • Consistent animal mechanisms have not yet resolved the limited human trial evidence or an effective treatment strategy.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial
Manal F Abdelmalek et al. · Hepatology (Baltimore, Md.) · 2009
Tier 2
Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase
Andrew S Lim et al. · Hepatology (Baltimore, Md.) · 2026
Tier 2
Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes
Ana Maria Grizales et al. · The Journal of clinical endocrinology and metabolism · 2018
Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021
Tier 4
Betaine in human nutrition
Stuart A S Craig et al. · The American journal of clinical nutrition · 2004

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology